Risk factors for estrogen receptor-positive breast cancer

被引:20
|
作者
Hwang, ES
Chew, T
Shiboski, S
Farren, G
Benz, CC
Wrensch, M
机构
[1] Univ Calif San Francisco, Ctr Canc, Dept Surg, San Francisco, CA 94115 USA
[2] Univ Calif San Francisco, Ctr Canc, Dept Epidemiol & Biostat, San Francisco, CA 94115 USA
[3] Marin Community Clin, San Rafael, CA USA
[4] Buck Inst Age Res, Novato, CA USA
关键词
D O I
10.1001/archsurg.140.1.58
中图分类号
R61 [外科手术学];
学科分类号
摘要
Hypothesis: Some risk factors associated with breast cancer may be more predictive of estrogen receptor (ER)positive than ER-negative tumors. Design: Survey of patients enrolled in a study of breast cancer risk factors. Setting: Community population in a northern California county. Patients: A total of 234 individuals diagnosed as having breast cancer between July 1, 1997, and June 30, 1999, reporting Marin County, California, residence and participating in a questionnaire regarding exposure to breast cancer risk factors. Main Outcome Measure: Diagnosis of ER-positive vs ER-negative breast cancer. Results: Comparison between ER-positive and ER-negative cases showed several factors predictive of ER-positive tumors. In a multivariate model, years of hormone therapy use remained the most significant predictor of ER-positive disease. Conclusions: Patients diagnosed as having ER-positive breast cancer were more likely to have undergone hormone therapy. The excess of ER-positive breast cancers reported in Marin County could, therefore, in part, be related to hormone therapy.
引用
收藏
页码:58 / 62
页数:5
相关论文
共 50 条
  • [41] Complete estrogen blockade in advanced postmenopausal receptor-positive breast cancer
    [J]. Nature Clinical Practice Oncology, 2008, 5 (2): : 67 - 67
  • [42] Synaptotagmin 13 Is Highly Expressed in Estrogen Receptor-Positive Breast Cancer
    Ichikawa, Takahiro
    Shibata, Masahiro
    Inaishi, Takahiro
    Soeda, Ikumi
    Kanda, Mitsuro
    Hayashi, Masamichi
    Takano, Yuko
    Takeuchi, Dai
    Tsunoda, Nobuyuki
    Kodera, Yasuhiro
    Kikumori, Toyone
    [J]. CURRENT ONCOLOGY, 2021, 28 (05) : 4080 - 4092
  • [43] Fulvestrant radiosensitizes human estrogen receptor-positive breast cancer cells
    Wang, Jing
    Yang, Qifeng
    Haffty, Bruce G.
    Li, Xiaoyan
    Moran, Meena S.
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2013, 431 (02) : 146 - 151
  • [44] The kinome associated with estrogen receptor-positive status in human breast cancer
    Bruce, M. Christine
    McAllister, Danielle
    Murphy, Leigh C.
    [J]. ENDOCRINE-RELATED CANCER, 2014, 21 (05) : R357 - R370
  • [45] A new marker of tamoxifen resistance of estrogen receptor-positive breast cancer
    Bogush, E. A.
    Ravcheeva, A. B.
    Bogush, T. A.
    Zabotina, T. N.
    Kadagidze, Z. G.
    Davydov, M. I.
    [J]. DOKLADY BIOCHEMISTRY AND BIOPHYSICS, 2007, 413 (01) : 83 - 87
  • [46] Treatment strategy for metastatic breast cancer with estrogen receptor-positive tumor
    Hirotaka Iwase
    [J]. International Journal of Clinical Oncology, 2015, 20 : 249 - 252
  • [47] Role of Estrogen Receptor-Positive/Negative Ratios in Regulating Breast Cancer
    Li, Yanchu
    Zhang, Hengli
    Jiang, Tingting
    Li, Ping
    [J]. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2022, 2022
  • [48] microRNA Regulation in Estrogen Receptor-Positive Breast Cancer and Endocrine Therapy
    Erin W. Howard
    Xiaohe Yang
    [J]. Biological Procedures Online, 2018, 20
  • [49] The role of stat5 in estrogen receptor-positive breast cancer
    Hiroko Yamashita
    Hirotaka Iwase
    [J]. Breast Cancer, 2002, 9 (4) : 312 - 318
  • [50] Nanomedicine in therapeutic warfront against estrogen receptor-positive breast cancer
    Aalhate, Mayur
    Mahajan, Srushti
    Singh, Hoshiyar
    Guru, Santosh Kumar
    Singh, Pankaj Kumar
    [J]. DRUG DELIVERY AND TRANSLATIONAL RESEARCH, 2023, 13 (06) : 1621 - 1653